Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Nickel, M. K. Articles by Kaplan, P. Search for Related Content PubMed Citation Articles by Nickel, M. K. Articles by Kaplan, P. Neurotransmitters Anxiety Disorders (General) Depression Atypical Neuroleptics Borderline Personality Disorders Cognition

Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Placebo-Controlled Study

OBJECTIVE: Aripiprazole is a relatively new atypical antipsychotic agent that has been successfully employed in therapy for schizophrenia and schizoaffective disorders. A few neuroleptics have been used in therapy for patients with borderline personality disorder, which is associated with severe psychopathological symptoms. Aripiprazole, however, has not yet been tested for this disorder, and the goal of this study was to determine whether aripiprazole is effective in the treatment of several domains of symptoms of borderline personality disorder. METHOD: Subjects meeting criteria for the Structured Clinical Interview for DSM-III-R Personality Disorders for borderline personality disorder (43 women and 9 men) were randomly assigned in a 1:1 ratio to 15 mg/day of aripiprazole (N=26) or placebo (N=26) for 8 weeks. Primary outcome measures were changes in scores on the symptom checklist (SCL-90-R), the Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating Scale (HAM-A), and the State-Trait Anger Expression Inventory and were assessed weekly. Side effects and self-injury were assessed with a nonvalidated questionnaire. RESULTS: According to the intent-to-treat principle, significant changes in scores on most scales of the SCL-90-R, the HAM-D, the HAM-A, and all scales of the State-Trait Anger Expression Inventory were observed in the subjects treated with aripiprazole after 8 weeks. Self-injury occurred in the groups. The reported side effects were headache, insomnia, nausea, numbness, constipation, and anxiety. CONCLUSIONS: Aripiprazole appears to be a safe and effective agent in the treatment of patients with borderline personality disorder.

This article has been cited by other articles:

				G Martinotti, M Di Nicola, M Di Giannantonio, and L Janiri Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. Naltrexone J Psychopharmacol, March 1, 2009; 23(2): 123 - 129. [Abstract] [PDF]

				S. C. Schulz, M. C. Zanarini, A. Bateman, M. Bohus, H. C. Detke, Q. Trzaskoma, Y. Tanaka, D. Lin, W. Deberdt, and S. Corya Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study The British Journal of Psychiatry, December 1, 2008; 193(6): 485 - 492. [Abstract] [Full Text] [PDF]

				P. Leiberich, M. Nickel, K. Tritt, and F P. Gil Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up J Psychopharmacol, September 1, 2008; 22(7): 805 - 808. [Abstract] [PDF]

				Et al Evid. Based Ment. Health, February 1, 2007; 10(1): 7 - 8. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us